利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.028 秒)

    Salipro Particles
    12.
    发明申请
    Salipro Particles 有权
    Salipro粒子

    公开(公告)号：US20160082125A1

    公开(公告)日：2016-03-24

    申请号：US14649095

    申请日：2013-12-12

    申请人： Jens FRAUENFELD

    发明人： Jens Frauenfeld

    IPC分类号： A61K47/48 ,  A61K38/16 ,  A61K9/127

    CPC分类号： A61K47/6917 ,  A61K9/1274 ,  A61K9/1275 ,  A61K9/145 ,  A61K9/146 ,  A61K38/164 ,  A61K39/00 ,  A61K47/24 ,  A61K47/42 ,  A61K47/543 ,  A61K47/544 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6929

    摘要： The invention provides a nanoscale particle comprising a lipid binding polypeptide, lipids and a hydrophobic agent, wherein the hydrophobic agent is different from the lipids, and wherein the lipid binding polypeptide is a saposin-like protein or a derivative or truncated form thereof. The invention further provides a process for preparing a particle comprising a saposin-like protein or a derivative or truncated form thereof and lipids comprising the step of (a) contacting the saposin-like protein or a derivative or truncated form thereof with solubilized lipids in a liquid environment and (b) allowing for the self-assembly of the particle at a pH of from 5.0 to 10.0. In addition, the invention provides a pharmaceutical composition comprising the particle of the invention for delivering a hydrophobic agent to an individual in need thereof and includes the use of the particle of the invention in preventing, treating or lessening the severity of a disease or its use in a diagnostic method, a cosmetic treatment, as hydrophobic agent delivery particle, as a tool for drug development, drug screening, membrane protein research or as vaccination formulation.

    摘要翻译： 本发明提供了包含脂质结合多肽，脂质和疏水剂的纳米级颗粒，其中所述疏水剂不同于脂质，并且其中所述脂质结合多肽是类似于类似蛋白质的蛋白质或其衍生物或截短形式。 本发明还提供了一种制备包含类似于类似蛋白质的蛋白质或其衍生物或截短形式的颗粒和脂质的方法，所述脂质包括以下步骤：（a）将类似于类似蛋白质的蛋白质或其衍生物或截短形式与溶解的脂质接触 液体环境和（b）允许在5.0至10.0的pH下自组装颗粒。 此外，本发明提供了包含本发明的颗粒的药物组合物，用于将疏水剂递送至有需要的个体，并且包括使用本发明的颗粒来预防，治疗或减轻疾病的严重性或其用途 在诊断方法中，作为疏水剂递送颗粒的美容处理，作为药物开发，药物筛选，膜蛋白研究或疫苗制剂的工具。

    PARTICLES COMPRISING LUMINESCENT LANTHANIDE COMPLEXES
    13.
    发明申请
    PARTICLES COMPRISING LUMINESCENT LANTHANIDE COMPLEXES 审中-公开
    包含LUMINESCENT LANTHANIDE复合物的颗粒

    公开(公告)号：US20160030599A1

    公开(公告)日：2016-02-04

    申请号：US14776342

    申请日：2014-03-13

    申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)

    发明人： Eva Jakab Toth ,  Stéphane Petoud ,  Sara Lacerda ,  Célia Bonnet

    IPC分类号： A61K49/00 ,  A61K31/136 ,  A61K31/4745 ,  A61K31/704

    CPC分类号： A61K49/0084 ,  A61K31/136 ,  A61K31/137 ,  A61K31/4745 ,  A61K31/704 ,  A61K47/6911 ,  A61K47/6917 ,  A61K49/008

    摘要： The present invention relates to particles, useful for drug release detection, comprising: at least one luminescent metal complex of formula [Ln].[L], wherein: Ln is a lanthanide ion, L is an organic ligand comprising a hydrophilic unit with at least 6 chelating groups chosen from the group consisting of hydroxyl, carboxyl, optionally in the carboxylate form, carbonyl, ether, phosphonate, phosphinate, thiolate, amino and imino functions, and at least one drug comprising a conjugated aromatic system, wherein said drug is not covalently bonded to the metal complex, said particle having a size comprised from 3 nm to 2000 nm, and wherein the distribution of the metal complex and the drug within the particle is such that the mean distance between a drug molecule and a metal complex is less than 15 nm.

    摘要翻译： 本发明涉及用于药物释放检测的颗粒，其包含：至少一种式[Ln]的发光金属络合物[L]，其中：Ln是镧系元素离子，L是包含亲水单元的有机配体， 选自羟基，羧基，任选以羧酸盐形式，羰基，醚，膦酸盐，次膦酸盐，硫醇盐，氨基和亚氨基官能团的至少6个螯合基团，和至少一种包含共轭芳族体系的药物，其中所述药物是 所述颗粒具有3nm至2000nm的尺寸，并且其中金属络合物和药物在颗粒内的分布使得药物分子和金属络合物之间的平均距离为 小于15nm。

    Biomimetic iron-oxide-containing lipoprotein and related materials
    15.
    发明授权
    Biomimetic iron-oxide-containing lipoprotein and related materials 有权
    含模拟氧化铁的脂蛋白及相关材料

    公开(公告)号：US08361494B2

    公开(公告)日：2013-01-29

    申请号：US12282308

    申请日：2007-03-06

    申请人： I-Wei Chen ,  Hoon Choi

    发明人： I-Wei Chen ,  Hoon Choi

    IPC分类号： A61K9/127 ,  A61K49/18

    CPC分类号： A61K49/1806 ,  A61K47/6917 ,  A61K49/1839 ,  B82Y5/00

    摘要： An engineered lipoprotein including (a) a core particle or a plurality of core particles, each core particle has (i) an inner part comprising a hydrophilic active agent and a hydrophilic portion of an amphiphilic cholesterol and (ii) an outer part including a hydrophobic portion of the amphiphilic cholesterol, (b) a layer surrounding the core particle or a plurality of core particles, the layer includes a phospholipid, (c) an apoprotein associated with the layer, and optionally, (d) a homing molecule associated with at least one of the apoprotein or the phospholipid.

    摘要翻译： 工程化脂蛋白包括（a）核心颗粒或多个核心颗粒，每个核心颗粒具有（i）内部部分，其包含亲水性活性剂和两亲性胆固醇的亲水部分，和（ii）包含疏水性的外部部分 两亲性胆固醇的部分，（b）围绕核心颗粒或多个核心颗粒的层，该层包括磷脂，（c）与该层相关的脱辅基蛋白，以及任选地，（d） 至少一种脱辅基蛋白或磷脂。

    "> HIGH-DENSITY LIPOPROTEIN-LIKE PEPTIDE-PHOSPHOLIPID SCAFFOLD (
    16.
    发明申请
    HIGH-DENSITY LIPOPROTEIN-LIKE PEPTIDE-PHOSPHOLIPID SCAFFOLD ("HPPS") NANOPARTICLES 审中-公开
    高密度脂蛋白样肽 - 磷脂酰胆碱（“HPPS”）纳米颗粒

    公开(公告)号：US20110020242A1

    公开(公告)日：2011-01-27

    申请号：US12747815

    申请日：2008-12-12

    申请人： Gang Zheng ,  Zhihong Zhang ,  Ian Corbin ,  Juan Chen

    发明人： Gang Zheng ,  Zhihong Zhang ,  Ian Corbin ,  Juan Chen

    IPC分类号： A61K49/14 ,  C07K17/02 ,  A61K49/00 ,  A61K9/14 ,  A61P35/00

    CPC分类号： A61K49/0082 ,  A61K47/6917 ,  A61K47/6919 ,  A61K49/0002 ,  A61K49/0032 ,  A61K49/0056 ,  B82Y5/00 ,  G01N33/54346 ,  G01N33/587 ,  G01N2800/00

    摘要： The present invention provides a non-naturally occurring High-Density Lipoprotein-like peptide-phospholipid scaffold (“HPPS”) nanoparticle. More particularly, the invention provides a non-naturally occurring peptide-lipid nanoscaffold comprising: (a) at least one phospholipid; (b) at least one unsaturated lipid, preferably an unsaturated sterol ester, further preferably an unsaturated cholesterol ester, further preferably cholsteryl oleate; and (c) at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; wherein the components a), b) and c) associate to form the peptide-phospholipid nanoscaffold. In embodiments of the present invention, a cell surface receptor ligand is incorporated into the HPPS. In one embodiment, the cell surface receptor ligand is covalently bonded to the peptide scaffold of the HPPS nanoparticles. In other embodiments, a cell surface receptor ligand is coupled to a lipid anchor and is displayed on the surface of the HPPS nanoparticles by incorporation of the lipid anchor into the phospholipids monolayer of the HPPS nanoparticle. The present invention also provides pharmaceutical formulations comprising HPPS nanoparticles and methods of making the HPPS nanoparticles.

    摘要翻译： 本发明提供非天然存在的高密度脂蛋白样肽 - 磷脂支架（“HPPS”）纳米颗粒。 更具体地，本发明提供非天然存在的肽 - 脂质纳米支架，其包含：（a）至少一种磷脂; （b）至少一种不饱和脂质，优选不饱和甾醇酯，更优选不饱和胆固醇酯，更优选油酸胆甾醇酯; 和（c）至少一种肽，所述肽包含能够形成至少一种两亲性α-螺旋的氨基酸序列; 其中组分a），b）和c）缔合形成肽 - 磷脂纳米支架。 在本发明的实施方案中，将细胞表面受体配体掺入HPPS中。 在一个实施方案中，细胞表面受体配体共价键合到HPPS纳米颗粒的肽支架上。 在其它实施方案中，将细胞表面受体配体偶联到脂质锚定物上，并通过将脂质锚点掺入HPPS纳米颗粒的磷脂单层中而显示在HPPS纳米颗粒的表面上。 本发明还提供了包含HPPS纳米颗粒的药物制剂和制备HPPS纳米颗粒的方法。

    Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells
    17.
    发明申请
    Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells 审中-公开
    用于将化合物递送至组织或细胞的截短载脂蛋白B的脂蛋白颗粒

    公开(公告)号：US20030008014A1

    公开(公告)日：2003-01-09

    申请号：US09885894

    申请日：2001-06-20

    发明人： Gregory S. Shelness

    IPC分类号： A61K038/17 ,  A61K009/50 ,  C07K014/775

    CPC分类号： A61K9/1275 ,  A61K47/6849 ,  A61K47/6917

    摘要： A lipoprotein compound delivery particle comprises: (a) a lipophilic or amphipathic compound to be delivered (e.g. paclitaxel); (b) at least one polar lipid (this ingredient being optional when the lipophilic or amphipathic compound serves itself as a polar lipid); (c) optionally, at least one neutral lipid; and (d) a truncated apolipoprotein B (apoB) protein having a deleted LDL receptor binding region. Conjugates useful for making such particles, pharmaceutical formulations containing such particles, and methods of using such particles are also described.

    摘要翻译： 脂蛋白化合物递送颗粒包括：（a）待递送的亲脂性或两亲性化合物（例如紫杉醇）; （b）至少一种极性脂质（当亲脂性或两亲性化合物本身作为极性脂质时，该成分是任选的）; （c）任选的至少一种中性脂质; 和（d）具有缺失的LDL受体结合区的截短的载脂蛋白B（apoB）蛋白。 还描述了可用于制备这种颗粒的缀合物，含有这种颗粒的药物制剂，以及使用这种颗粒的方法。